We are international
• health professionals TEXT SIZE   
webcasts    back

Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Rotterdam, Netherlands
Member, IMF Board of Scientific Advisors

Be the first to comment

 related articles